{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-014788","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.646456+00:00","generated_at":"2026-06-16T12:57:30.225053+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viking Therapeutics Q1 net loss $19.5M; VK2735 shows up to 7.8% weight loss","bullets":["Net loss $19.5M ($0.25/sh) vs $16.1M ($0.21/sh) in Q1 2022; R&D $11.0M, G&A $9.5M.","Cash and investments $135.7M at March 31; pro forma with $287.5M offering totals ~$406M.","VK2735 Phase 1: up to 7.8% mean weight loss from baseline (6% placebo-adjusted); half-life 170-250h; no discontinuations for GI AEs.","Phase 2b VOYAGE study of VK2809 for NASH fully enrolled; primary endpoint data expected in Q2 2023.","Phase 1 oral formulation of VK2735 initiated; data expected 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-014788","json":"https://secwatch.observer/filing/0000950170-23-014788.json","markdown":"https://secwatch.observer/filing/0000950170-23-014788.md","text":"https://secwatch.observer/filing/0000950170-23-014788.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023014788/0000950170-23-014788-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023014788/vktx-20230426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T12:57:30.225053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"98699b1c26eafd39d178c99efa69a71e88a24c7c","claim":"Viking Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"announced its financial results for the first quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023014788/0000950170-23-014788-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}